Middle East & Africa Patient-derived Xenograft Model Market Size & Outlook
Middle East & Africa patient-derived xenograft model market, 2018-2030 (US$M)
Related Markets
MEA patient-derived xenograft model market highlights
- The MEA patient-derived xenograft model market generated a revenue of USD 6.9 million in 2024.
- The market is expected to grow at a CAGR of 6.6% from 2025 to 2030.
- In terms of segment, breast cancer was the largest revenue generating tumor type in 2024.
- Lung Cancer is the most lucrative tumor type segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2025 to 2030.
MEA data book summary
| Market revenue in 2024 | USD 6.9 million |
| Market revenue in 2030 | USD 10.2 million |
| Growth rate | 6.6% (CAGR from 2024 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Lung Cancer |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Lung Cancer, Pancreatic Cancer, Prostrate Cancer, Breast Cancer, Other Cancer |
| Key market players worldwide | Charles River Laboratories International Inc, The Jackson Laboratory, Crown Holdings Inc, Inotiv Inc, Wuxi AppTec Co Ltd, OncoCyte Corp, Alteogen, XenTech, Abnova |
Other key industry trends
- In terms of revenue, MEA region accounted for 2.4% of the global patient-derived xenograft model market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 97.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Patient-derived Xenograft Model Market Scope
Patient-derived Xenograft Model Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa patient-derived xenograft model market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to patient-derived xenograft model market will help companies and investors design strategic landscapes.
Breast cancer was the largest segment with a revenue share of 31.88% in 2024. Horizon Databook has segmented the Middle East & Africa patient-derived xenograft model market based on lung cancer, pancreatic cancer, prostrate cancer, breast cancer, other cancer covering the revenue growth of each sub-segment from 2018 to 2030.
- Middle East & Africa Patient-derived Xenograft Model Tumor Type Outlook (Revenue, USD Million, 2018-2030)
- Lung Cancer
- Pancreatic Cancer
- Prostrate Cancer
- Breast Cancer
- Other Cancer
- Middle East & Africa Patient-derived Xenograft Model Model Type Outlook (Revenue, USD Million, 2018-2030)
- Mice Model
- Rat Model
- Middle East & Africa Patient-derived Xenograft Model End Use Outlook (Revenue, USD Million, 2018-2030)
- Pharmaceutical and Biopharmaceutical Companies
- Accademic and Research Institutes
- CROs and CDMOs
Reasons to subscribe to Middle East & Africa patient-derived xenograft model market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa patient-derived xenograft model market databook
-
Our clientele includes a mix of patient-derived xenograft model market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa patient-derived xenograft model market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa patient-derived xenograft model market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA patient-derived xenograft model market size, by country, 2018-2030 (US$M)
Middle East & Africa Patient-derived Xenograft Model Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
